Engineered immune cells take on Hard-to-Treat blood cancers
NCT ID NCT02153580
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 29 times
Summary
This early-phase study tests a personalized cell therapy for adults with certain B-cell blood cancers that have returned after prior treatment. Doctors take a patient's own white blood cells, modify them in a lab to better recognize and attack cancer cells, and infuse them back after a short course of chemotherapy. The main goals are to check safety and find the best dose, while also monitoring how long the modified cells last in the body and whether the cancer shrinks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.